Last reviewed · How we verify
Active Ingredient
The drug, developed by Clinical Research Centre, Malaysia, is currently marketed but lacks detailed public information on its active ingredient, mechanism, and primary indication, making its precise market position unclear. A key strength is the protection offered by the key composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of revenue data and key trial results, which may limit the drug's visibility and competitive positioning in the market.
At a glance
| Generic name | Active Ingredient |
|---|---|
| Sponsor | Clinical Research Centre, Malaysia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease (PHASE3)
- Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics (NA)
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
- The Effects of a Probiotic Food Supplement in Hyperuricaemia (NA)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- LDART for Alcohol Use Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Ingredient CI brief — competitive landscape report
- Active Ingredient updates RSS · CI watch RSS
- Clinical Research Centre, Malaysia portfolio CI